Catalyst4, Inc. - 28 Oct 2025 Form 4 Insider Report for MapLight Therapeutics, Inc. (MPLT)

Role: 10%+ Owner
Signature: /s/ Robert Brown
Issuer symbol: MPLT
Transactions as of: 28 Oct 2025
Net transactions value: +$92,499,992
Form type: 4
Filing time: 29 Oct 2025, 16:16:55 UTC
Previous filing: 27 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Catalyst4, Inc.	10%+ Owner	555 BRYANT STREET #376, PALO ALTO	/s/ Robert Brown	29 Oct 2025	0001900201

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MLPT	Voting Common Stock	Conversion of derivative security		+14,256,288			14,256,288	28 Oct 2025	See footnote	F1, F2
transaction	MLPT	Voting Common Stock	Purchase	$92,499,992	+5,441,176	+38%	$17.00	19,697,464	28 Oct 2025	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MLPT	Series A Preferred Stock	Conversion of derivative security		-148,809	-100%		0	28 Oct 2025	Voting Common Stock	148,809		See footnote	F2, F3
transaction	MLPT	Series A-1 Preferred Stock	Conversion of derivative security		-444,846	-100%		0	28 Oct 2025	Voting Common Stock	444,846		See footnote	F2, F4
transaction	MLPT	Series B Preferred Stock	Conversion of derivative security		-1,263,768	-100%		0	28 Oct 2025	Voting Common Stock	1,263,768		See footnote	F2, F5
transaction	MLPT	Series B-1 Preferred Stock	Conversion of derivative security		-275,148	-100%		0	28 Oct 2025	Voting Common Stock	275,148		See footnote	F2, F6
transaction	MLPT	Series C Preferred Stock	Conversion of derivative security		-5,444,807	-100%		0	28 Oct 2025	Voting Common Stock	5,444,807		See footnote	F2, F7
transaction	MLPT	Series D Preferred Stock	Conversion of derivative security		-6,678,910	-100%		0	28 Oct 2025	Voting Common Stock	6,678,910		See footnote	F2, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Series A, A-1, B, B-1, C and D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
F2	The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.
F3	The Series A Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
F4	The Series A-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
F5	The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.
F6	The Series B-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
F7	The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
F8	The Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.